NasdaqGS - Nasdaq Real Time Price USD

IDEXX Laboratories, Inc. (IDXX)

553.57 -2.23 (-0.40%)
As of 10:08:39 am GMT-4. Market open.
Chart Range Bar
Loading chart for IDXX
  • Previous close 555.80
  • Open 559.14
  • Bid 559.19 x 100
  • Ask 501.77 x 100
  • Day's range 553.57 - 561.83
  • 52-week range 500.61 - 769.98
  • Volume 43,543
  • Avg. Volume 547,906
  • Market cap (intra-day) 43.667B
  • Beta (5Y monthly) 1.55
  • PE ratio (TTM) 38.90
  • EPS (TTM) 14.23
  • Earnings date 2 Nov 2026
  • Forward dividend & yield -- (0.00%)
  • Ex-dividend date --
  • 1y target est 698.00

IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

www.idexx.com

11,000

Full-time employees

31 December

Fiscal year ends

Healthcare

Sector

Diagnostics & Research

Industry

Performance overview

Trailing total returns as of 20/10/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD return

IDXX
18.18%
S&P 500 (^GSPC)
12.68%

1-year return

IDXX
13.96%
S&P 500 (^GSPC)
14.53%

3-year return

IDXX
29.64%
S&P 500 (^GSPC)
82.61%

5-year return

IDXX
13.80%
S&P 500 (^GSPC)
70.05%

Earnings trends

View more

Earnings per share

GAAP
Normalised
GAAP
Normalised
 

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 1.22B
Earnings 338.41M
Profit margin 27.82%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
200M
400M
600M
800M
1B
1B
23.0%
24.0%
25.0%
26.0%
27.0%
 

Analyst insights

View more

Analysts' price targets

470.00 Low
698.00 Average
553.57 Current
805.00 High
 

Analyst recommendations

  • Strong buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Latest rating

Date 16/10/2026
Analyst JP Morgan
Rating action Maintains
Rating Overweight
Price action Lowers
Price target 775 -> 750
 

Statistics

View more

Valuation measures

As of 22/09/2026
  • Market cap

    41.08B

  • Enterprise value

    41.98B

  • Trailing P/E

    36.65

  • Forward P/E

    31.45

  • PEG ratio (5-yr expected)

    2.85

  • Price/sales (ttm)

    9.18

  • Price/book (mrq)

    25.48

  • Enterprise value/revenue

    9.22

  • Enterprise value/EBITDA

    25.98

Financial highlights

Profitability and income statement

  • Profit margin

    25.03%

  • Return on assets (ttm)

    27.09%

  • Return on equity (ttm)

    74.21%

  • Revenue (ttm)

    4.55B

  • Net income avi to common (ttm)

    1.14B

  • Diluted EPS (ttm)

    14.23

Balance sheet and cash flow

  • Total cash (mrq)

    196.93M

  • Total debt/equity (mrq)

    67.97%

  • Levered free cash flow (ttm)

    909.37M

Compare

Select to analyse similar companies using key performance metrics; select up to four stocks.

People also watch